College of Pharmaceutical Science & Collaborative Innovation Center of Yangtze River Delta Region Green Pharmaceuticals, Zhejiang University of Technology, Hangzhou, China; Macau University of Science and Technology, State Key Laboratory of Quality Research in Chinese Medicines, Macao.
Department of Infectious Diseases, The First Affiliated Hospital of Anhui Medical University & Anhui Center for Surveillance of Bacterial Resistance, Hefei, China.
Drug Discov Today. 2022 Jul;27(7):1862-1873. doi: 10.1016/j.drudis.2022.03.021. Epub 2022 Apr 4.
Clostridioides difficile bacteria can cause life-threatening diarrhea and colitis owing to limited treatment options and unacceptably high recurrence rates among infected patients. This necessitates the development of alternative routes for C. difficile treatment. Drug repurposing with new indications represents a proven shortcut. Here, we present a refined focus on 16 FDA-approved drugs that would be suitable for further development as potential anti-C. difficile drugs. Of these drugs, clinical trials have been conducted on five currently used drugs; however, ursodeoxycholic acid is the only drug to enter Phase IV clinical trials to date. Thus, drug repurposing promotes the study of mechanistic and therapeutic strategies, providing new options for the development of next-generation anti-C. difficile agents.
艰难梭菌可导致危及生命的腹泻和结肠炎，由于治疗选择有限，感染患者的复发率高得令人无法接受。这就需要开发治疗艰难梭菌的替代途径。药物再利用具有新的适应症，这是一条经过验证的捷径。在这里，我们重点介绍了 16 种已获得美国食品和药物管理局批准的药物，它们适合进一步开发为潜在的抗艰难梭菌药物。在这些药物中，有 5 种目前正在使用的药物已经进行了临床试验；然而，熊去氧胆酸是迄今为止唯一一种进入第四阶段临床试验的药物。因此，药物再利用促进了对机制和治疗策略的研究，为开发下一代抗艰难梭菌药物提供了新的选择。
